DK152672B - METHOD FOR PREPARING 2-HYDROXYMETHYL-3-HYDROXY-6- (1-HYDROXY-2-T-BUTYLAMINOETHYL) PYRIDINE OR ACID ADDITION SALTS. - Google Patents

METHOD FOR PREPARING 2-HYDROXYMETHYL-3-HYDROXY-6- (1-HYDROXY-2-T-BUTYLAMINOETHYL) PYRIDINE OR ACID ADDITION SALTS. Download PDF

Info

Publication number
DK152672B
DK152672B DK188178AA DK188178A DK152672B DK 152672 B DK152672 B DK 152672B DK 188178A A DK188178A A DK 188178AA DK 188178 A DK188178 A DK 188178A DK 152672 B DK152672 B DK 152672B
Authority
DK
Denmark
Prior art keywords
hydroxy
butylaminoethyl
acid
water
acid addition
Prior art date
Application number
DK188178AA
Other languages
Danish (da)
Other versions
DK188178A (en
DK152672C (en
Inventor
Susumu Nakanishi
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of DK188178A publication Critical patent/DK188178A/en
Publication of DK152672B publication Critical patent/DK152672B/en
Application granted granted Critical
Publication of DK152672C publication Critical patent/DK152672C/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/65One oxygen atom attached in position 3 or 5

Description

Den foreliggende opfindelse angår en særlig fremgangsmåde til fremstilling af 2-hydroxymethyl-3-hydroxy-6-(l-hydroxy-2-t-butylaminoethyl)pyridin eller syreadditionssalte heraf ved fjernelse af benzyliden-beskyttelsesgruppen fra 2-phenyl-6-(l-hydroxy-2-t-butylaminoethyl)-4H-pyrido[3,2-d]-1,3-dioxin.The present invention relates to a particular process for the preparation of 2-hydroxymethyl-3-hydroxy-6- (1-hydroxy-2-t-butylaminoethyl) pyridine or acid addition salts thereof by removing the benzylidene protecting group from 2-phenyl-6- (1 -hydroxy-2-t-butylaminoethyl) -4H-pyrido [3,2-d] -1,3-dioxin.

I DSA-patentskrift nr. 3.948.919, udstedt 6. april 1976, er der beskrevet fremstillingen af 2-hydroxymethyl-3-hydroxy-6-(1-hydro-xy-2-t-butylaminoethyl)pyridin (betegnet med det generiske navn pir-buterol, formel IV), en bronchodilatator, ved følgende tre beslægtede reaktionsrækker:DSA Patent No. 3,948,919, issued April 6, 1976, discloses the preparation of 2-hydroxymethyl-3-hydroxy-6- (1-hydroxy-2-t-butylaminoethyl) pyridine (denoted by the generic name pir-buterol, formula IV), a bronchodilator, for the following three related reaction sequences:

Figure DK152672BD00031

I de ovenstående formler betegner R og R' hver phenyl eller methyl, og Z betegner -CHOH-CH2-NH-C(CH3)3·In the above formulas, R and R 'are each phenyl or methyl and Z is -CHOH-CH 2 -NH-C (CH 3) 3 ·

Reaktionsrækken IA til IB til IV giver gode udbytter af slutproduktet (IV) med god kvalitet, men har den økonomiske ulempe, at den kræver benzylbromid, et forholdsvis dyrt stof, som reaktant til fremstilling af benzyletheren (IA). Ved hydrogenolytisk fjernelse af benzylgruppen (IB til IV) opnås en vellykket fjernelse af de farvede urenheder.Reaction series IA to IB to IV give good yields of the end product (IV) of good quality, but have the economic disadvantage of requiring benzyl bromide, a relatively expensive substance, as a reactant for the production of the benzyl ether (IA). By hydrogenolytic removal of the benzyl group (IB to IV), a successful removal of the colored impurities is achieved.

Reaktionsrækken IIIA til HIB til IV er mindre attraktiv fra et økonomisk standpunkt end reaktionsrækken IIA til IIB til IV som følge af de forholdsvis høje omkostninger, der er forbundet med fremstillingen af reaktant IIIA.Reaction series IIIA to HIB to IV is less attractive from an economic standpoint than reaction series IIA to IIB to IV due to the relatively high costs associated with the production of reactant IIIA.

Reaktionsrækken HA til IIB til IV er fri for de ovennævnte ulemper. Ligesom de to andre reaktionsrækker er den imidlertid, navnlig ved drift i stor målestok, undergivet tilstedeværelsen af farvede urenheder i slutproduktet (IV). Disse urenheder opstår under fremstillingen af mellemprodukterne IB, IIB og IIIB og, medmindre de fjernes før omdannelsen af nævnte forbindelser til IV, eller som ved reaktionen IB til IV elimineres ved den hydrogenolytiske fjernelse af benzylgruppen, griber de forstyrrende ind i isoleringen og rensningen af produktet IV.Reaction series HA to IIB to IV are free of the above disadvantages. However, like the other two series of reactions, it is subject, in particular to large-scale operation, to the presence of colored impurities in the final product (IV). These impurities occur during the preparation of the intermediates IB, IIB and IIIB and unless they are removed before the conversion of said compounds to IV, or which in the reaction IB to IV are eliminated by the hydrogenolytic removal of the benzyl group, they interfere with the isolation and purification of the product. IV.

Beskyttelse af alifatiske hydroxylgrupper ved omdannelse af dem til benzylidenacetaler har fundet udstrakt anvendelse i sukker-og glyceridkemien. Benzylidengruppen kan fjernes ved katalytisk hy-drogenolyse under anvendelse af palladium—trækul (Peat et al., J. Chem.Soc., 1088, 1938) eller ved hydrolyse med en mineralsyre.Protection of aliphatic hydroxyl groups by converting them into benzylidene acetals has found widespread use in the sugar and glyceride chemistry. The benzylidene group can be removed by catalytic hydrogenolysis using palladium charcoal (Peat et al., J. Chem.Soc., 1088, 1938) or by hydrolysis with a mineral acid.

Fodor et al., Synthesis, 464-472 (1972) rapporterer anvendelsen af benzylidengruppen som beskyttelsesgruppe for hydroxylgrupper-ne i 2-methyl-5-hydroxy-6-hydroxymethylpyridin og 2,6-bis-hydroxy-methyl-3-hydroxypyridin, der er mellemprodukter ved fremstillingen af carpyrinsyre og beslægtede pyridiner. Katalytisk hydrogenering af benzylidenacetalen 2-phenyl-6-(11-tetrahydropyranyloxydodecen-l-yl)-4H-pyrido[3,2-d]-1,3-dioxin ved lavt tryk over platinoxid fjernede ikke benzylidengruppen, men hydrogenerede kun olefingruppen.Fodor et al., Synthesis, 464-472 (1972) report the use of the benzylidene group as the protecting group for the hydroxyl groups of 2-methyl-5-hydroxy-6-hydroxymethylpyridine and 2,6-bis-hydroxy-methyl-3-hydroxypyridine. there are intermediates in the preparation of carpyric acid and related pyridines. Catalytic hydrogenation of the benzylidene acetal 2-phenyl-6- (11-tetrahydropyranyloxydodecen-1-yl) -4H-pyrido [3,2-d] -1,3-dioxin at low pressure over platinum oxide did not remove the benzylidene group but only hydrogenated the olefin group.

I USA-patentskrift nr. 4.011.231, udstedt 8. marts 1977, er der beskrevet fremstillingen af pirbuterol-dihydrochlorid af høj kva- , litet ved en fremgangsmåde, som omfatter omsætning af maleinsyre med 2-phenyl-6-(l-hydroxy-2-t-butylaminoethyl)-4H-pyrido[3,2-d]-1,3-di-oxin til dannelse af maleatsaltet deraf, efterfulgt af hydrolyse af dioxinet med overskud af saltsyre. Omdannelse af det således fremstillede dihydrochlorid til f.eks. acetatet ved simpel ombytning er ikke praktisk gennemførlig af økonomiske grunde, idet den kræver et yderligere trin, og udbytterne ikke. er tilfredsstillende.U.S. Patent No. 4,011,231, issued March 8, 1977, discloses the preparation of high quality pirbuterol dihydrochloride by a process comprising reacting maleic acid with 2-phenyl-6- (1-hydroxy) 2-t-Butylaminoethyl) -4H-pyrido [3,2-d] -1,3-dioxin to form the maleate salt thereof, followed by hydrolysis of the dioxin with excess hydrochloric acid. Conversion of the dihydrochloride thus produced to e.g. The acetate by simple exchange is not practically feasible for economic reasons, requiring an additional step and the yields do not. Is satisfying.

Fremgangsmåden ifølge opfindelsen er ejendommelig ved, at man hydrogenolyserer den sidstnævnte forbindelse over palladium-på-kul som katalysator i en alkohol med op til 4 carbonatomer som opløsningsmiddel i nærværelse af fra 1 til 30 molækvivalenter vand pr. mol 2-phenyl-6-(l-hydroxy-2-t-butylaminoethyl)-4H-pyri-do[3,2-d]-1,3-dioxin, hvorefter den hydrogenolyserede reaktions-, blanding filtreres og koncentreres til fjernelse af vandet, hvorefter 2-hydroxymethyl-3-hydroxy-6-(l-hydroxy-2-t-butylaminoethyl)-pyridin opnås som base ved yderligere koncentrering eller fås i form. af et syreadditionssalt ved behandling med mindst den støkiometriske mængde af en syre.The process of the invention is characterized in that the latter is hydrogenolysed over palladium-on-carbon as a catalyst in an alcohol having up to 4 carbon atoms as solvent in the presence of from 1 to 30 molar equivalents of water per liter. mole of 2-phenyl-6- (1-hydroxy-2-t-butylaminoethyl) -4H-pyrido [3,2-d] -1,3-dioxin, then the hydrogenolyzed reaction, mixture is filtered and concentrated to remove of the water, after which 2-hydroxymethyl-3-hydroxy-6- (1-hydroxy-2-t-butylaminoethyl) -pyridine is obtained as a base by further concentration or obtained in form. of an acid addition salt by treatment with at least the stoichiometric amount of an acid.

Fremgangsmåden ifølge den foreliggende opfindelse er en modifikation af den i USA-patentskrift nr. 3.948.919 beskrevne reaktionsrække IIA til IIB til IV, ved hvilken modifikation der opnås en betydelig forbedring i udbytte og renhed ved fremstilling af pirbute-rol i stor målestok. I forhold til de i USA-patentskrift nr. 3.948.919 beskrevne fremgangsmåder medfører denne fremgangsmåde en forøget økonomisk fordel. Fremgangsmåden omfatter hydrogenolyse af benzyliden-acetalen 2-phenyl-6-(l-hydroxy-2-t-butylaminoethyl)-4H-pyrido[3,2-d]-1,3-dioxin IIB til pirbuterol.The process of the present invention is a modification of the reaction series IIA to IIB to IV described in U.S. Patent No. 3,948,919, wherein modification achieves a significant improvement in yield and purity in large-scale pirbuteurol production. Compared to the methods disclosed in U.S. Patent No. 3,948,919, this method provides an added economic benefit. The process comprises hydrogenolysis of the benzylidene-acetal 2-phenyl-6- (1-hydroxy-2-t-butylaminoethyl) -4H-pyrido [3,2-d] -1,3-dioxin IIB to pirbuterol.

Denne.fremgangsmåde giver uventet en fordelagtig, økonomisk, direkte og industrielt anvendelig vej til acetatsaltet eller til andre syreadditionssalte, navnlig med ikke-mineralsyrer, af pirbuterol.This process unexpectedly provides an advantageous, economically, directly and industrially useful route to the acetate salt or to other acid addition salts, especially with non-mineral acids, of pirbuterol.

Fjernelse af benzyliden-beskyttelsesgruppen fra IIB ved hydrolyse kræver en stærk syre, fortrinsvis en mineralsyre, såsom saltsyre, hydrogenbromidsyre eller svovlsyre, til opnåelse af tilfredsstillende omdannelse til pirbuterol. Sur hydrolyse kan ikke fjerne de tilstedeværende farvede urenheder. Disse urenheder føres over i slutproduktet (IV) og er vanskelige at fjerne. Desuden opnås pirbuterol-produktet som syreadditionssaltet af den til hydrolysen anvendte syre, f.eks. dihydrochloridsaltet.Removal of the benzylidene protecting group from IIB by hydrolysis requires a strong acid, preferably a mineral acid, such as hydrochloric acid, hydrobromic acid or sulfuric acid, to achieve satisfactory conversion to pirbuterol. Acid hydrolysis cannot remove the colored impurities present. These impurities are transferred into the final product (IV) and are difficult to remove. In addition, the pirbuterol product is obtained as the acid addition salt of the acid used for the hydrolysis, e.g. dihydrochloride.

Omdannelse af dihydrochloridsaltet, eller andet mineralsyre-additionssalt, til acetatet eller andet ikke-mineralsyresalt ved simpel ombytning er ikke økonomisk gennemførlig eller industrielt gen- nemførlig med et tilfredsstillende udbytte af et tilstrækkelig rent produkt. Den foreliggende hydrogenolysefremgangsmåde giver pirbuterol af høj kvalitet som den frie base og muliggør således dets direkte omdannelse til acetatet eller ethvert andet ønsket syreadditionssalt, der ligesom pirbuterol finder anvendelse som bronchodilatator. Ikke-mineralsyrer, såsom eddikesyre eller andre alkansyrer, giver ikke tilfredsstillende fjernelse af benzyliden-beskyttelsesgruppen fra UB og er derfor ikke økonomisk attraktive til dette formål.Conversion of the dihydrochloride salt, or other mineral acid addition salt, to the acetate or other non-mineral acid salt by simple exchange is not economically feasible or industrially feasible with a satisfactory yield of a sufficiently pure product. The present hydrogenolysis process provides high-quality pirbuterol as the free base and thus enables its direct conversion to the acetate or any other desired acid addition salt which, like pirbuterol, finds use as a bronchodilator. Non-mineral acids, such as acetic or other alkanoic acids, do not provide satisfactory removal of the benzylidene protecting group from UB and are therefore not economically attractive for this purpose.

Der kan benyttes forskellige hensigtsmæssige udførelsesformer for fremgangsmåden ifølge opfindelsen som angivet i krav 2-5.Various convenient embodiments of the method according to the invention can be used as set forth in claims 2-5.

Ved fremgangsmåden ifølge den foreliggende opfindelse hydro-genolyseres benzylidenacetalen, formel XIB, i nærværelse af pal— ladium-på-kul i et reaktionsindifferent opløsningsmiddel til fjernelse af benzyliden-beskyttelsesgruppen og dannelse af pirbuterol (formel IV) af høj kvalitet, hvilket reaktionsindifferente opløsningsmiddel er en alkohol med op til 4 carbonatomer. Methanol foretrækkes, da det giver kvantitativ fjernelse af beskyttelsesgruppen, er forholdsvis billigt og let tilgængeligt og kan tjene som reaktionsmedium for efterfølgende saltdannelse. Der ma være vand til stede under hydrogenolysen for at begrænse sidereaktioner mest muligt.In the process of the present invention, the benzylidene acetal, Formula XIB, is hydrogenated in the presence of palladium-on-carbon in a reaction inert solvent to remove the benzylidene protecting group and form high quality pirbuterol (Formula IV) which is reaction inert solvent. an alcohol of up to 4 carbon atoms. Methanol is preferred as it provides quantitative removal of the protecting group, is relatively inexpensive and readily available, and can serve as the reaction medium for subsequent salt formation. Water must be present during hydrogenolysis to minimize side reactions.

Reaktionen udføres almindeligvis ved en temperatur på fra ca. 20°C til 25°C, hvor den forløber glat og- kvantitativt til det ønskede produkt, pirbuterol. Endvidere svarer denne temperatur i det væsentlige til stuetemperatur og kræver ikke nogen afkøling eller opvarmning. Reaktionstemperaturen er ikke væsentlig. Der kan benyttes lavere eller højere temperaturer, f.eks. fra ca. 10 C til ca. 100 C, men dette indebærer ikke nogen fordele. Tværtimod, fra et synspunkt om omkostninger undgås temperaturer uden for området fra 20 til 25 C.The reaction is usually carried out at a temperature of from ca. 20 ° C to 25 ° C, where it runs smoothly and quantitatively to the desired product, pirbuterol. Furthermore, this temperature is substantially equivalent to room temperature and does not require any cooling or heating. The reaction temperature is not significant. Lower or higher temperatures may be used, e.g. from approx. 10 C to approx. 100 C, but this does not bring any benefits. On the contrary, from a cost perspective, temperatures outside the range of 20 to 25 C are avoided.

Hydrogentrykket er ikke væsentligt. Tryk på fra ca. 0,07 til ca. 14 kg/cm^ kan benyttes til fjernelse af beskyttelsesgruppen. Af økonomiske grunde og for at lette driften anvendes der imidlertid i 2 virkelig praksis tryk på fra 1 til 10 kg/cm .Hydrogen pressure is not significant. Press from approx. 0.07 to approx. 14 kg / cm 2 can be used to remove the protecting group. However, for economic reasons and to facilitate operation, pressures from 1 to 10 kg / cm are used in 2 real practice.

Som katalysator er 50% palladium-pa-kul særlig effektivt med hensyn til at opnå hurtig og fuldstændig fjernelse af benzyli dengruppen.As a catalyst, 50% palladium carbon is particularly effective in achieving rapid and complete removal of the benzyl in that group.

Den anvendte mængde katalysator er ikke væsentlig for heldig gennemførelse af denne fremgangsmåde. I virkelig praksis har fra ca.The amount of catalyst used is not essential for successful implementation of this process. In real practice, from approx.

0,01 til ca. 0,10 g palladium pr. gram benzylidenacetal vist sig i høj grad tilfredsstillende til at gennemføre fjernelse af benzyliden-gruppen. Udtrykt i 5% palladium på trækul er dette ækvivalent med fra ca. 0,2 til 2,0 g af 5% palladium på trækul pr. gram benzylidenacetal.0.01 to approx. 0.10 g palladium per grams of benzylidene acetal have been found to be highly satisfactory for the removal of the benzylidene group. Expressed in 5% palladium on charcoal, this is equivalent to from approx. 0.2 to 2.0 g of 5% palladium on charcoal grams of benzylidene acetal.

En sidereaktion ved denne hydrogenolyseproces er hydrogenolyse af hydroxylgruppen på p-butylaminoethylgruppen i 6-stillingen. Ved tilstedeværelse af vand under hydrogenolysereaktionen opnår man, at denne sidereaktion begrænses mest muligt eller endog undgås. Medens tilstedeværelsen af vand er væsentlig, kan vandmængden variere fra 1 mol-ækvivalent til så meget som 30 mol-ækvivalenter, baseret på benzylidenacetalen, idet den begrænsende faktor er fortyndingsvirkningen af det tilsatte vand på hastigheden af den ønskede hydrogeno lys er eakt ion . Den foretrukne mængde vand er fra 1 til ca. 20 molækvivalenter. Tilstedeværelsen af mindre mængder vand tjener til formindskelse af denne sidereaktion, men med mindre effektivitet end mængder inden for det ovennævnte område gør det. Større mængder vand er tilbøjelige til at formindske hastigheden for hydrogenolysereaktionen som anført.A side reaction to this hydrogenolysis process is hydrogenolysis of the hydroxyl group on the p-butylaminoethyl group at the 6-position. By the presence of water during the hydrogenolysis reaction, it is achieved that this side reaction is minimized or even avoided. While the presence of water is substantial, the amount of water can range from 1 mole equivalent to as much as 30 mole equivalent, based on the benzylidene acetal, the limiting factor being the dilution effect of the added water on the rate of the desired hydrogen o light being the ect ion. The preferred amount of water is from 1 to approx. 20 molar equivalents. The presence of smaller amounts of water serves to reduce this side reaction, but with less efficiency than amounts within the above range. Larger amounts of water tend to decrease the rate of hydrogenolysis reaction as stated.

Tilstedeværelsen af vand ved hydrogenolysereaktionen til mest mulig begrænsning af den ovennævnte sidereaktion opfyldes bekvemt ved anvendelse af palladium-på-trækul-katalysatoren i form af vand-vædet materiale, f.eks. 50% vandvædet materiale. De ovennævnte katalysatormængder bliver da fra ca. 0,4 til ca. 4,0 g af 5% palladium på trækul, 50% vandvædet, pr. gram benzylidenacetal. Alternativt sættes vandet særskilt til reaktionsblandingen.The presence of water in the hydrogenolysis reaction to limit as much as possible the above-mentioned side reaction is conveniently met by using the palladium-on-charcoal catalyst in the form of water-wetted material, e.g. 50% water soaked material. The above-mentioned catalyst amounts will then be from approx. 0.4 to approx. 4.0 g of 5% palladium on charcoal, 50% water wet, per grams of benzylidene acetal. Alternatively, the water is added separately to the reaction mixture.

Hydrogenolysereaktionsblandingen, der indeholder pirbuterol i form af den frie base, filtreres og koncentreres, sædvanligvis under formindsket tryk, til et lille rumfang til fjernelse af vand og som biprodukt dannet toluen. Til mere effektiv tørring af koncentratet tilsættes der ethanol, sædvanligvis fra ca. 1 til 2 rumfang, og den opnåede opløsning koncentreres. Dette trin gentages om nødvendigt eller ønsket til mere fuldstændig fjernelse af tilstedeværende vand. Ved fuldstændig fjernelse af alle opløsningsmidler og som biprodukt dannet toluen opnås den frie base som et fast stof, der er forholdsvis stabilt ved omgivende temperaturer, f.eks. 20-25°C.The hydrogenolysis reaction mixture containing pirbuterol in the form of the free base is filtered and concentrated, usually under reduced pressure, to a small volume for removal of water and as a by-product of toluene. For more efficient drying of the concentrate, ethanol is usually added, usually from ca. 1 to 2 volumes and the solution obtained is concentrated. This step is repeated if necessary or desired for more complete removal of water present. By complete removal of all solvents and toluene formed as a by-product, the free base is obtained as a solid which is relatively stable at ambient temperatures, e.g. 20-25 ° C.

Det ønskede syreadditionssalt af pirbuterol fremstilles let ved at sætte den pågældende syre, f.eks. eddikesyre, til koncentratet. Der tilsættes mindst den støkiometriske mængde. I praksis sæt- tes der op til 10% overskud af syren til koncentratet. For at fremskynde udfældningen af syreadditionssaltet tilsættes syren sædvanligvis som en opløsning i et opløsningsmiddel, f.eks. acetone, i hvilket syreadditionssaltet er uopløseligt. Alternativt sættes nævnte opløsningsmiddel til koncentratet før, efter eller samtidigt med syren.The desired acid addition salt of pirbuterol is readily prepared by adding the acid in question, e.g. acetic acid, to the concentrate. At least the stoichiometric amount is added. In practice, up to 10% excess of the acid is added to the concentrate. To accelerate the precipitation of the acid addition salt, the acid is usually added as a solution in a solvent, e.g. acetone, in which the acid addition salt is insoluble. Alternatively, said solvent is added to the concentrate before, after or simultaneously with the acid.

Det ved denne fremgangsmåde fremstillede pirbuterol er uventet og overraskende fri for farvede urenheder. Den hydrogenolytiske fjernelse af benzyliden-beskyttelsesgruppen giver således et kvantitativt udbytte af pirbuterol af høj kvalitet og muliggør derfor fremstilling af syreadditionssalte af pirbuterol af høj kvalitet. Den muliggør anvendelse af rå benzylidenacetal og fremstilling af et rent debenzyleret produkt. Et yderligere træk ved den hydrogenoly tiske fjernelse af benzyliden-beskyttelsesgruppen er dannelsen af toluen, et biprodukt der let fjernes fra reaktionsblandingen. I modsætning hertil dannes der ved hydrolytisk fjernelse af benzylidengrup-pen benzaldehyd, som vanskeligere fjernes fra reaktionsblandingen.The pirbuterol prepared by this method is unexpectedly and surprisingly free of colored impurities. Thus, the hydrogenolytic removal of the benzylidene protecting group provides a quantitative yield of high quality pirbuterol and therefore enables the production of high quality pirbuterol acid addition salts. It enables the use of crude benzylidene acetal and the preparation of a pure debenzylated product. A further feature of the hydrogenolytic removal of the benzylidene protecting group is the formation of toluene, a by-product easily removed from the reaction mixture. In contrast, by the hydrolytic removal of the benzylidene group benzaldehyde is formed, which is more difficult to remove from the reaction mixture.

Fremgangsmåden ifølge opfindelsen belyses nærmere ved hjælp af de efterfølgende eksempler.The process according to the invention is further elucidated by the following examples.

Eksempel 1Example 1

Pirbuterolacetat.Pirbuterol acetate.

En opløsning af 2-phenyl-6-(l-hydroxy-2-t-butylaminoethyl)-4H-pyrido[3,2-d]-1,3-dioxin (1,67 kg, 5,09 mol) i methanol (16,7 liter) sættes til en glasforet reaktor påfyldt 5% palladium-på-trækulkatalysator, 50% vandvædet (2,13 kg, 11,6 mol-ækvivalenter vand). Blandingen omrøres, og reaktoren udrenses med nitrogen og derefter med hydrogen. Reaktoren påfyldes hydrogen ved 3,5 kg/cm ved 20-25 C og holdes på dette niveau under hele reaktionstiden på 12 timer.Reaktoren trykaflastes, og reaktionsblandingen filtreres gennem diatomS-jord. (Tyndtlagschromatografi i systemet methylethylketon:eddikesyre? vand [6:1:1 vol/vol] på silicagel GF-plader viste, at hydrogenolysen var fuldstændig). Filterkagen vaskes med methanol (3 x 500 ml), og den samlede vaskevæske og filtrat behandles med aktivt trækul (167 g), omrøres ved 20-25°C i 1 time og filtreres derpå. Et rumfang filtrat indeholdende 1 mol pirbuterol fjernes og koncentreres til ca.A solution of 2-phenyl-6- (1-hydroxy-2-t-butylaminoethyl) -4H-pyrido [3,2-d] -1,3-dioxin (1.67 kg, 5.09 mol) in methanol (16.7 liters) is added to a glass-lined reactor filled with 5% palladium-on-charcoal catalyst, 50% water wet (2.13 kg, 11.6 molar equivalents of water). The mixture is stirred and the reactor is purified with nitrogen and then with hydrogen. The reactor is charged with hydrogen at 3.5 kg / cm at 20-25 C and maintained at this level for the entire reaction time of 12 hours. The reactor is pressure relieved and the reaction mixture is filtered through diatom S soil. (Thin-layer chromatography in the system methyl ethyl ketone: acetic acid? Water [6: 1: 1 v / v] on silica gel GF plates showed that the hydrogenolysis was complete). The filter cake is washed with methanol (3 x 500 ml) and the combined washing liquid and filtrate are treated with activated charcoal (167 g), stirred at 20-25 ° C for 1 hour and then filtered. A volume of filtrate containing 1 mole of pirbuterol is removed and concentrated to ca.

1/3 rumfang under formindsket tryk. Ethanol (2550 ml) sættes til koncentratet, og den opnåede opløsning koncentreres til 1/3 rumfang under formindsket tryk. Tilsætningen af ethanol og koncentreringen gentages 3 eller flere gange til sikring af et vandfrit koncentrat af pirbuterol.1/3 volume under reduced pressure. Ethanol (2550 ml) is added to the concentrate and the solution obtained is concentrated to 1/3 volume under reduced pressure. The addition of ethanol and the concentration are repeated 3 or more times to ensure an anhydrous concentrate of pirbuterol.

Pirbuterolet omdannes til dets acetatsalt ved tilsætning af en opløsning af iseddikesyre (67,3 g, 1,12 mol) i acetone (6125 ml) til koncentratet. Den opnåede blanding omrøres og opvarmes til 50-55°C og afkøles derefter til stuetemperatur i et vandbad. Acetatsaltet udkrystalliseres og frafiltreres, vaskes med acetone (2 x 500 ml) og tørres i vakuum ved 20-25°C. Udbytte = 222 g (75%), smp. 154-155 c. Analyse: Beregnet for C^2H20<^3N2’('2H4O2: C ^5,99, H 8,05, N 9,33%, fundet: C 56,60, H 8,16, N 9,56%.The pirbuterol is converted to its acetate salt by adding a solution of glacial acetic acid (67.3 g, 1.12 mole) in acetone (6125 ml) to the concentrate. The resulting mixture is stirred and heated to 50-55 ° C and then cooled to room temperature in a water bath. The acetate salt is crystallized and filtered off, washed with acetone (2 x 500 ml) and dried in vacuo at 20-25 ° C. Yield = 222 g (75%), m.p. 154-155 c. Analysis: Calculated for C₂ 2H₂ <<33N2 ′ (2H4O2: C ^ 5.99, H 8.05, N 9.33%, found: C 56.60, H 8.16, N 9.56%.

Ved omkrystallisation af ethanol opnås en analytisk prøve: Analyse: Fundet: C 56,04, H 8,05, N 9,33%.Upon recrystallization of ethanol, an analytical sample is obtained: Analysis: Found: C 56.04, H 8.05, N 9.33%.

Den resterende methanolopløsning af pirbuterol koncentreres på den ovenfor beskrevne måde, og ethanol-pirbuterol-koncentratet behandles med den støkiometriske mængde fumarsyre, og blandingen om-røres og opvarmes til 60°C. Fumaratsaltet fælder ud, og opslemningen omrøres og henstilles til afkøling til 25°C. Den afkøles derefter i et isbad til 5°C, granuleres i 30 minutter og filtreres derpå. Filterkagen vaskes med ethanol og tørres i en ovn med tvungen luftcir— kulation ved 50°C (73% udbytte baseret pa den antagelse, at der er 4,09 mol pirbuterol i koncentratet). Produktet er hemifumaratmono-ethanolatsaltet. Smp. 135-136°C (sønderdeling).The remaining methanol solution of pirbuterol is concentrated in the manner described above, and the ethanol-pirbuterol concentrate is treated with the stoichiometric amount of fumaric acid and the mixture is stirred and heated to 60 ° C. The fumarate salt precipitates and the slurry is stirred and left to cool to 25 ° C. It is then cooled in an ice bath to 5 ° C, granulated for 30 minutes and then filtered. The filter cake is washed with ethanol and dried in a forced air circulation oven at 50 ° C (73% yield based on the assumption that there are 4.09 moles of pirbuterol in the concentrate). The product is the hemifumarate mono-ethanolate salt. Mp. 135-136 ° C (dec.).

Analyse: Beregnet for ci2H20°3N2’1//2 C4H4°4*C2H5OH: C 55,80, H 8,19, N 8,14%, fundet: C 55,72, H 8,25, N 8,06%.Analysis: Calculated for C 21 H 20 ° 3 N 2 · 1 // 2 C 4 H 4 ° 4 * C 2 H 5 OH: C 55.80, H 8.19, N 8.14%, found: C 55.72, H 8.25, N 8.06 %.

Eksempel 2Example 2

Fremgangsmåden ifølge eksempel 1 gentages, idet der dog anvendes 0,049 mol 2-phenyl-6-(l-hydroxy-2-t-butylaminoethyl)-4H-pyri-do[3,2-d]-1,3-dioxin, 160 ml methanol som opløsningsmiddel, 20,38 g 5% palladium-på-trækul, 50% vandvædet (11,5 mol-ækvivalenter vand) og et hydrogentryk på 3,5 kg/cm2 ved 22°C i 22,5 timer til opnåelse af 100% omdannelse til pirbuterol.The procedure of Example 1 is repeated, however, using 0.049 moles of 2-phenyl-6- (1-hydroxy-2-t-butylaminoethyl) -4H-pyrido [3,2-d] -1,3-dioxin, 160 20 ml of methanol as solvent, 20.38 g of 5% palladium-on-charcoal, 50% of water (11.5 molar equivalent water) and a hydrogen pressure of 3.5 kg / cm 2 at 22 ° C for 22.5 hours to obtain of 100% conversion to pirbuterol.

Ved behandling af ethanolkoncentratet, opnået som beskrevet i eksempel 1, med 0,055 mol iseddikesyre opnas 73% udbytte af pirbute— rolacetat.By treating the ethanol concentrate obtained as described in Example 1 with 0.055 moles of glacial acetic acid 73% yield of pirbutyl acetate is obtained.

Eksempel 3Example 3

Pirbuterolacetat (ved hydrogenolyse under anvendelse af 1 mol-ækvivalent vand).Pirbuterol acetate (by hydrogenolysis using 1 mole equivalent of water).

En opløsning af 2—phenyl—6—(l-hydroxy-2-t-butylaminoethyl)-4H-pyrido[3,2-d]-1,3-dioxin (8,046 g, 0,0245 mol) i methanol (80 ml) sættes til en 500-ml højtryksflaske påfyldt tør 5% palladium-på-træ-kul-katal-ysator (5,095 g) og vand (0,45 ml, 1 mol-ækvivalent). Blandingen omrøres, og reaktoren udrenses først med nitrogen og derefter med hydrogen. Reaktoren påfyldes hydrogen ved 3,5 kg/cm ved 20-25 C og holdes på dette niveau under hele reaktionstiden på 24 timer. Reaktoren trykaflastes, og reaktionsblandingen filtreres gennem diatoméjord. Filterkagen vaskes med methanol (2 x 30 ml), den samlede vaskevæske og filtrat behandles med aktivt kul (0,6 g), omrøres ved 20-25°C i 15 minutter og filtreres derefter gennem diatoméjord. Filterkagen vaskes med ethanol (2 x 12,5 ml), og det samlede filtrat og vaskevæske koncentreres under formindsket tryk til et rumfang på ca. 25 ml.A solution of 2-phenyl-6- (1-hydroxy-2-t-butylaminoethyl) -4H-pyrido [3,2-d] -1,3-dioxin (8.046 g, 0.0245 mol) in methanol (80 ml) is added to a 500-ml high-pressure bottle filled with dry 5% palladium-on-charcoal catalyst (5.095 g) and water (0.45 ml, 1 mole equivalent). The mixture is stirred and the reactor is first purified with nitrogen and then with hydrogen. The reactor is charged with hydrogen at 3.5 kg / cm at 20-25 C and maintained at this level for the entire reaction time of 24 hours. The reactor is pressurized and the reaction mixture is filtered through diatomaceous earth. The filter cake is washed with methanol (2 x 30 ml), the combined washing liquid and filtrate treated with activated carbon (0.6 g), stirred at 20-25 ° C for 15 minutes and then filtered through diatomaceous earth. The filter cake is washed with ethanol (2 x 12.5 ml) and the combined filtrate and wash liquid concentrated under reduced pressure to a volume of approx. 25 ml.

Iseddikesyre (1,618 g, 0,02695 mol) i acetone (1,50 ml) sættes til koncentratet, og den opnåede blanding omrøres og opvarmes til 50-55°C. Den afkøles derefter til stuetemperatur natten over og derpå til 0-5°C. Opløsningen koncentreres derefter under formindsket tryk til en olie (da der ikke indtrådte krystallisation), og der sættes chloroform (100 ml) til olien. Blandingen omrøres ved stuetemperatur i 2 timer, og acetatsaltet frafiltreres, vaskes med chloroform (2 x 15 ml) og tørres. Udbytte = 7,0 g (95,1%), smp. 152-154°C.Glacial acetic acid (1.618 g, 0.02695 mol) in acetone (1.50 ml) is added to the concentrate and the resulting mixture is stirred and heated to 50-55 ° C. It is then cooled to room temperature overnight and then to 0-5 ° C. The solution is then concentrated under reduced pressure to an oil (since no crystallization occurred) and chloroform (100 ml) is added to the oil. The mixture is stirred at room temperature for 2 hours and the acetate salt is filtered off, washed with chloroform (2 x 15 ml) and dried. Yield = 7.0 g (95.1%), m.p. 152-154 ° C.

Eksempel 4Example 4

Fremgangsmåden ifølge eksempel 3 gentages, idet der dog anvendes de nedenfor anførte vandmængder.The procedure of Example 3 is repeated, however, using the quantities of water listed below.

Figure DK152672BD00101

Acetatet udkrystalliserede af koncentratet ved afkøling. Det forholdsvis lave udbytte skyldes ufuldstændig fjernelse af vandet fra koncentratet før dannelse af acetatsaltet.The acetate crystallized from the concentrate upon cooling. The relatively low yield is due to incomplete removal of the water from the concentrate before formation of the acetate salt.

NMR viser tilstedeværelsen af 2-hydroxymethyl-3-hydroxy-6-(2-t-bu-tylaminoethyl)pyridin som urenhed.NMR shows the presence of 2-hydroxymethyl-3-hydroxy-6- (2-t-butylaminoethyl) pyridine as impurity.

Figure DK152672BD00111

^a· Dioxin = 2-phenyl-6-(l-hydroxy-2-t-butylaminoethyl)-4H-pyrido[3,2-d]-1,3-dioxin. ^vand tilsat særskilt; katalysator tilsat i tør tilstand.dioxin = 2-phenyl-6- (1-hydroxy-2-t-butylaminoethyl) -4H-pyrido [3,2-d] -1,3-dioxin. ^ water added separately; catalyst added in dry state.

Figure DK152672BD00121

I hvert enkelt tilfælde fremstilles der pirbuterol af høj kvalitet.In each case, high quality pirbuterol is produced.

Claims (5)

1. Fremgangsmåde til fremstilling af 2-hydroxymethyl-3-hydro-xy-6-(l-hydroxy-2-t-butylaminoethyl)pyridin eller syreadditionssalte heraf ved fjernelse af benzyliden-beskyttelsesgruppen fra 2-phenyl-6-(l-hydroxy-2-t-butylaminoethyl)-4H-pyrido[3,2-d]-1,3-dioxin, kendetegnet ved, at man hydrogenolyserer den sidstnævnte forbindelse over palladium-på-kul som katalysator i en alkohol med op til 4 carbonatomer som opløsningsmiddel i nærværelse af fra 1 til 30 molækvivalenter vand pr. mol 2-phenyl-6-(l-hydroxy-2-t-bu-tylaminoethyl)-4H-pyrido[3,2-d]-1,3-dioxin, hvorefter den hydrogeno-lyserede reaktionsblanding filtreres og koncentreres til fjernelse af vandet, hvorefter 2-hydrcxymethyl-3-hydroxy-6-(l-hydroxy-2-t-butyl-aminoethyl)pyridin opnås som base ved yderligere koncentrering eller fås i form af et syreadditionssalt ved behandling med mindst den støkiometriske mængde af en syre.A process for preparing 2-hydroxymethyl-3-hydroxy-6- (1-hydroxy-2-t-butylaminoethyl) pyridine or acid addition salts thereof by removing the benzylidene protecting group from 2-phenyl-6- (1-hydroxy) -2-t-butylaminoethyl) -4H-pyrido [3,2-d] -1,3-dioxin, characterized by hydrogenolysing the latter compound over palladium-on-carbon as a catalyst in an alcohol of up to 4 carbon atoms as a solvent in the presence of from 1 to 30 molar equivalents of water per mole of 2-phenyl-6- (1-hydroxy-2-t-butylaminoethyl) -4H-pyrido [3,2-d] -1,3-dioxin, then the hydrogenolysed reaction mixture is filtered and concentrated to remove the water, then 2-hydroxymethyl-3-hydroxy-6- (1-hydroxy-2-t-butylaminoethyl) pyridine is obtained as a base by further concentration or obtained in the form of an acid addition salt by treatment with at least the stoichiometric amount of an acid . 2. Fremgangsmåde ifølge krav 1, kendetegnet ved, at palladium-på-kul anvendes som 50% vandvædet materiale.Process according to claim 1, characterized in that palladium-on-coal is used as 50% water-wet material. 3. Fremgangsmåde ifølge krav 1 eller 2, kendetegnet ved, at hydrogenolysen udføres ved omgivelsernes temperatur ved et 2 hydrogentryk på fra 1 til 10 kg/cm .Process according to claim 1 or 2, characterized in that the hydrogenolysis is carried out at ambient temperature at a hydrogen pressure of 1 to 10 kg / cm. 4. Fremgangsmåde ifølge et vilkårligt af kravene 1-3, kendetegnet ved, at opløsningsmidlet er methanol.Process according to any one of claims 1-3, characterized in that the solvent is methanol. 5. Fremgangsmåde ifølge et vilkårligt af kravene 1-4, k e n -detegnet ved, at syren er eddikesyre.Process according to any one of claims 1-4, characterized in that the acid is acetic acid.
DK188178A 1977-05-02 1978-05-01 METHOD FOR PREPARING 2-HYDROXYMETHYL-3-HYDROXY-6- (1-HYDROXY-2-T-BUTYLAMINOETHYL) PYRIDINE OR ACID ADDITION SALTS THEREOF DK152672C (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US79281477A 1977-05-02 1977-05-02
US79281477 1977-05-02
US88369078A 1978-03-06 1978-03-06
US88369078 1978-03-06

Publications (3)

Publication Number Publication Date
DK188178A DK188178A (en) 1978-11-03
DK152672B true DK152672B (en) 1988-04-11
DK152672C DK152672C (en) 1988-08-22

Family

ID=27121337

Family Applications (1)

Application Number Title Priority Date Filing Date
DK188178A DK152672C (en) 1977-05-02 1978-05-01 METHOD FOR PREPARING 2-HYDROXYMETHYL-3-HYDROXY-6- (1-HYDROXY-2-T-BUTYLAMINOETHYL) PYRIDINE OR ACID ADDITION SALTS THEREOF

Country Status (10)

Country Link
AR (1) AR214005A1 (en)
CA (1) CA1074322A (en)
CH (1) CH631445A5 (en)
DK (1) DK152672C (en)
FI (1) FI67541C (en)
IT (1) IT1112681B (en)
LU (1) LU79564A1 (en)
NL (1) NL175412C (en)
PT (1) PT67968B (en)
YU (1) YU40330B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9784726B2 (en) 2013-01-08 2017-10-10 Atrogi Ab Screening method, a kit, a method of treatment and a compound for use in a method of treatment
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB202205895D0 (en) 2022-04-22 2022-06-08 Atrogi Ab New medical uses

Also Published As

Publication number Publication date
FI67541B (en) 1984-12-31
LU79564A1 (en) 1979-11-07
YU40330B (en) 1985-12-31
FI67541C (en) 1985-04-10
PT67968A (en) 1978-05-01
NL7804582A (en) 1978-11-06
NL175412B (en) 1984-06-01
NL175412C (en) 1984-11-01
CA1074322A (en) 1980-03-25
FI781329A (en) 1978-11-03
DK188178A (en) 1978-11-03
DK152672C (en) 1988-08-22
PT67968B (en) 1979-11-14
AR214005A1 (en) 1979-04-11
IT1112681B (en) 1986-01-20
CH631445A5 (en) 1982-08-13
IT7822863A0 (en) 1978-04-28
YU91378A (en) 1982-10-31

Similar Documents

Publication Publication Date Title
AU2008298943B2 (en) Process and intermediates for preparing integrase inhibitors
US5290941A (en) Facile condensation of methylbenzoxazoles with aromatic aldehydes
CA2878699C (en) Process and intermediates for preparing integrase inhibitors
JPS5951956B2 (en) Synthesis method of 9-hydroxyellipticine derivative
DK152672B (en) METHOD FOR PREPARING 2-HYDROXYMETHYL-3-HYDROXY-6- (1-HYDROXY-2-T-BUTYLAMINOETHYL) PYRIDINE OR ACID ADDITION SALTS.
KR101269491B1 (en) Preparation method for entecavir
US4031108A (en) 2-Hydroxymethyl-3-benzyloxypyridine-6-epoxyethane
JPS638368A (en) 4-benzyloxy-3-pyrroline-2-one-1-ylacetamide,manufacture and use
CN109265385B (en) Synthesis process of chiral catalyst
US4231962A (en) 3-Phenoxybenzylideneamines and 3-benzylbenzylideneamines
CA1037047A (en) 2-hydroxymethyl-3-hydroxy-6-(1-hydroxy-2-t-butylaminoethyl)pyridine preparation and intermediate compounds
CN108203396B (en) Synthesis of enkephalinase inhibitor
Reese Facile preparation of acetals and enol ethers derived from 1-arylpiperidin-4-ones
US4011231A (en) 2-Phenyl-6-(1-hydroxy-2-t-butylaminoethyl)-4H-pyrido[3,2-d]-1,3-dioxin maleate and its use as an intermediate
CA3085475A1 (en) A process for the preparation of crisaborole
SU1711674A3 (en) Method for the synthesis of azonium spironortropanol ester
KR20140128998A (en) Process for the preparation of 2-phenyl-[1,2,4]triazolo[1,5-a]pyridine derivatives
CN110143909B (en) Preparation method of bilirubin intermediate
KR20080104314A (en) Process for preparing l-nucleic acid derivatives and intermediates thereof
EP0058071B1 (en) Process and intermediates for preparing pirbuterol
CN113121414A (en) Synthetic method of trelagliptin intermediate
CN116891415A (en) Preparation method of 2- [2- (2-aminoethoxy) ethoxy ] ethanol
CN113336753A (en) Riociguat synthesis method
CN113603634A (en) Preparation method of atazanavir intermediate
KR800000904B1 (en) Process for preparing 2-hydroxy methyl-3-hydroxy-6-(1-hydroxy-2-t-butylaminoethyl)pyridines

Legal Events

Date Code Title Description
PUP Patent expired